Astrogen Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 34

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $9.6M

  • Investors
  • 19

Astrogen General Information

Description

Operator of a clinical and research-oriented biotech company intended to help in drug development for intractable neurological diseases. The company's drug development is performed through clinician-led clinical research and collaboration among clinicians, medicinal chemists, nurses, pharmacists, and caregivers, enabling medical professionals to develop treatments with improved efficacy, safety, ease of administration, and patentability.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 440, Hyuksin-Daero
  • Dong
  • Daegu, Gyeongsang
  • South Korea
+82
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 440, Hyuksin-Daero
  • Dong
  • Daegu, Gyeongsang
  • South Korea
+82

Astrogen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Astrogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 15-Jan-2024 $9.6M Completed Clinical Trials - Phase 3
5. Accelerator/Incubator 23-Oct-2023 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 23-Jan-2022 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 14-Dec-2020 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 01-Aug-2019 $4.24M $5.93M Completed Clinical Trials - Phase 1
1. Seed Round 01-Aug-2018 $1.69M $1.69M Completed Clinical Trials - Phase 1
To view Astrogen’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Astrogen Patents

Astrogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026014835-A1 Liposome formulation of l-serine and method for preparing same Pending 12-Jul-2024
US-12606518-B2 Crystalline form of l-serine and process of preparing same Active 10-Jul-2024
US-20260015312-A1 New crystalline form of l-serine and process of preparing same Active 10-Jul-2024
WO-2026014573-A1 Novel crystal form of l-serine and method for preparing same Pending 10-Jul-2024
EP-4831163-A1 Improved method for preparation of (s)-biloxazine or salt thereof Pending 18-Dec-2023 C07D265/30
To view Astrogen’s complete patent history, request access »

Astrogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Astrogen Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
S&S Investment Venture Capital Minority
Xquared Venture Capital Minority
BiiG WAVE Accelerator/Incubator
iM Investment Partners Corporate Venture Capital Minority
JCH Investment Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Astrogen Investments (1)

Astrogen’s most recent deal was a Corporate Asset Purchase with Korea Land and Housing (Daegu-Gyeongbuk Advanced Medical Complex in Daegu, South Korea) for . The deal was made on 12-Jun-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Korea Land and Housing (Daegu-Gyeongbuk Advanced Medical Complex in Daegu, South Korea) 12-Jun-2022 Corporate Asset Purchase Buildings and Property
To view Astrogen’s complete investments history, request access »

Astrogen FAQs

  • When was Astrogen founded?

    Astrogen was founded in 2017.

  • Where is Astrogen headquartered?

    Astrogen is headquartered in Daegu, South Korea.

  • What is the size of Astrogen?

    Astrogen has 34 total employees.

  • What industry is Astrogen in?

    Astrogen’s primary industry is Drug Discovery.

  • Is Astrogen a private or public company?

    Astrogen is a Private company.

  • What is Astrogen’s current revenue?

    The current revenue for Astrogen is .

  • How much funding has Astrogen raised over time?

    Astrogen has raised $34.8M.

  • Who are Astrogen’s investors?

    S&S Investment, Xquared, BiiG WAVE, iM Investment Partners, and JCH Investment are 5 of 19 investors who have invested in Astrogen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process